UK healthcare workers begin COVID-19 hydroxychloroquine trial

LONDON: British healthcare workers will on Thursday (May 21) begin taking part in a University of Oxford-led international trial of two anti-malarial drugs to see if they can prevent COVID-19, including one US President Donald Trump says he has been taking.

The "COPCOV" study will involve more than 40,000 frontline healthcare workers from Europe, Africa, Asia and South America to determine if chloroquine and hydroxychloroquine are effective in preventing the novel coronavirus.

Advertisement

Advertisement

The drugs have risen to prominence since Trump said earlier this week he was taking hydroxychloroquine as a preventive medicine against the virus despite medical warnings about its use.

READ: COVID-19 patients given malaria drug did not see significant improvements: Studies

The trial, led by the University of Oxford with the support of the Mahidol Oxford Tropical Medicine Research Unit (MORU) in Bangkok, will open to British participants at hospital sites in Brighton and Oxford on Thursday and involve those who are in close contact with patients with proven or suspected COVID-19.

"We really do not know if chloroquine or hydroxychloroquine are beneficial or harmful against COVID-19," said the University of Oxford's Professor Nicholas White, the study's co-principal investigator who is based at MORU.

Advertisement

Advertisement

"The best way to find out if they are effective in preventing COVID-19 is in a randomised clinical trial."

READ: Commentary: COVID-19 treatment researchers should be cooperating not trash-talking each other

In Britain, Europe and Africa participants will receive either hydroxychloroquine or a placebo for three months. In Asia they will receive either chloroquine or a placebo.

A total of 25 study sites are expected toRead More – Source